Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Filters applied: . Clear all
The following term was not found in PubMed: of
Page 1
Familial hypercholesterolemia: Review of diagnosis, screening, and treatment.
Turgeon RD, Barry AR, Pearson GJ. Turgeon RD, et al. Can Fam Physician. 2016 Jan;62(1):32-7. Can Fam Physician. 2016. PMID: 26796832 Free PMC article. Review.
A supporting level of evidence for each recommendation was categorized as level I (randomized controlled trial or systematic review of randomized controlled trials), level II (observational study), or level III (expert opinion). The best available evidence is mostly level …
A supporting level of evidence for each recommendation was categorized as level I (randomized controlled trial or systematic review of rando …
Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
Gouni-Berthold I, Descamps OS, Fraass U, Hartfield E, Allcott K, Dent R, März W. Gouni-Berthold I, et al. Br J Clin Pharmacol. 2016 Dec;82(6):1412-1443. doi: 10.1111/bcp.13066. Epub 2016 Oct 4. Br J Clin Pharmacol. 2016. PMID: 27478094 Free PMC article. Review.
AIMS: Two anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, alirocumab and evolocumab, have been approved for the treatment of hypercholesterolaemia in certain patients. ...Both antibodies were effective and well tolerated across a broad pop …
AIMS: Two anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, alirocumab and evolocumab, have been appr …
Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Peng W, Qiang F, Peng W, Qian Z, Ke Z, Yi L, Jian Z, Chongrong Q. Peng W, et al. Int J Cardiol. 2016 Nov 1;222:119-129. doi: 10.1016/j.ijcard.2016.07.239. Epub 2016 Jul 30. Int J Cardiol. 2016. PMID: 27494723 Review.
The primary choice of therapy for controlling lipidemia has been statins, which are not completely effective. Proprotein convertase subtilisin/kexin type-9 (PCSK9), which interferes with LDL clearance from circulation, inversely relates to the LDL-C levels. ...
The primary choice of therapy for controlling lipidemia has been statins, which are not completely effective. Proprotein convertase subtilis …